| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.22▲ | 1.22▲ | 1.23▼ | 1.23▼ | 1.37▼ |
| MA10 | 1.22▲ | 1.21▲ | 1.21▲ | 1.29▼ | 1.46▼ |
| MA20 | 1.21▲ | 1.20▲ | 1.21▲ | 1.37▼ | 1.66▼ |
| MA50 | 1.20▲ | 1.24▼ | 1.27▼ | 1.52▼ | 1.75▼ |
| MA100 | 1.21▲ | 1.29▼ | 1.34▼ | 1.70▼ | N/A |
| MA200 | 1.25▼ | 1.36▼ | 1.41▼ | 1.80▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.006▲ | 0.008▲ | -0.013▼ | -0.039▼ |
| RSI | 60.171▲ | 52.475▲ | 47.971▼ | 36.896▼ | 34.380▼ |
| STOCH | 40.873 | 76.667 | 78.889 | 23.337 | 16.617▼ |
| WILL %R | -57.143 | -26.667 | -26.667 | -79.687▼ | -92.973▼ |
| CCI | 64.052 | 55.556 | 58.970 | -107.438▼ | -126.148▼ |
| ▲ RSI | $OSTX RSI(14) Crossed Above 30 | Set Alert |
|
Friday, February 13, 2026 08:24 AM
Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...
|
|
Wednesday, February 04, 2026 10:02 AM
OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon Give ...
|
|
Thursday, January 29, 2026 01:05 PM
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/02/26 | 1.17 | 1.245 | 1.17 | 1.225 | 214,698 |
| 12/02/26 | 1.19 | 1.21 | 1.16 | 1.16 | 277,503 |
| 11/02/26 | 1.25 | 1.26 | 1.18 | 1.20 | 814,592 |
| 10/02/26 | 1.30 | 1.31 | 1.24 | 1.26 | 425,754 |
| 09/02/26 | 1.40 | 1.42 | 1.198 | 1.30 | 1,996,995 |
| 06/02/26 | 1.30 | 1.435 | 1.295 | 1.36 | 631,067 |
| 05/02/26 | 1.35 | 1.35 | 1.255 | 1.27 | 634,219 |
| 04/02/26 | 1.42 | 1.42 | 1.29 | 1.33 | 648,819 |
| 03/02/26 | 1.42 | 1.45 | 1.38 | 1.41 | 367,275 |
| 02/02/26 | 1.38 | 1.41 | 1.31 | 1.39 | 607,650 |
|
|
||||
|
|
||||
|
|